These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25171759)

  • 1. The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia.
    Santos PC; Morgan AC; Jannes CE; Krieger JE; Santos RD; Pereira AC
    Pharmacogenet Genomics; 2014 Nov; 24(11):548-55. PubMed ID: 25171759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
    Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYLIP p.N342S polymorphism is not associated with lipid profile in the Brazilian population.
    Santos PC; Oliveira TG; Lemos PA; Mill JG; Krieger JE; Pereira AC
    Lipids Health Dis; 2012 Jun; 11():83. PubMed ID: 22741812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
    Mata N; Alonso R; Badimón L; Padró T; Fuentes F; Muñiz O; Perez-Jiménez F; López-Miranda J; Díaz JL; Vidal JI; Barba A; Piedecausa M; Sanchez JF; Irigoyen L; Guallar E; Ordovas JM; Mata P
    Lipids Health Dis; 2011 Jun; 10():94. PubMed ID: 21663647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
    Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
    Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
    García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
    Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans.
    Weissglas-Volkov D; Calkin AC; Tusie-Luna T; Sinsheimer JS; Zelcer N; Riba L; Tino AM; Ordoñez-Sánchez ML; Cruz-Bautista I; Aguilar-Salinas CA; Tontonoz P; Pajukanta P
    J Clin Invest; 2011 Aug; 121(8):3062-71. PubMed ID: 21765216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.
    Raal FJ; Pappu AS; Illingworth DR; Pilcher GJ; Marais AD; Firth JC; Kotze MJ; Heinonen TM; Black DM
    Atherosclerosis; 2000 Jun; 150(2):421-8. PubMed ID: 10856535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Willrich MA; Arazi SS; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
    Lipids Health Dis; 2011 Nov; 10():206. PubMed ID: 22074026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
    Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
    van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
    J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
    Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.
    Sinzinger H; Kritz H; Furberg CD
    Med Sci Monit; 2003 Jul; 9(7):PI88-92. PubMed ID: 12883464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.